Information Provided By:
Fly News Breaks for July 6, 2015
VRTX
Jul 6, 2015 | 07:43 EDT
Baird raised its price target on Vertex to $160 from $131 after Orkambi received FDA approval and the company announced pricing for the drug that was substantially higher than the firm had modeled. Baird maintains its Outperform rating on Vertex shares.
News For VRTX From the Last 2 Days
There are no results for your query VRTX